UK Locks Pharma Patent Protections into Swiss Trade Deal, Sparking NHS Cost Concerns
Key Insights
The UK has agreed to freeze existing pharmaceutical intellectual property protections, including 10-year RDP and 5-year SPC terms, as part of a new trade deal with Switzerland.
This marks the first time the UK has explicitly written drug patent rules into a trade agreement, preventing either country from shortening exclusivity periods without breaching terms.
Health campaigners warn the deal entrenches a system that could increase NHS medicines costs and limits future governments' ability to regulate in the public interest.
The United Kingdom has agreed to lock in controversial intellectual property protections for pharmaceutical firms as part of a newly upgraded trade deal with Switzerland, a move that has reignited debate over the balance between incentivizing drug innovation and controlling NHS medicines costs.
The agreement, announced on Monday, freezes existing patent protection rules, meaning neither country will be able to shorten exclusivity periods or bring cheaper generic medicines to market more quickly without breaching its terms. This marks the first time the UK has explicitly written drug patent rules into a trade deal.
Trade Minister Chris Bryant rejected the suggestion that agreeing to the pharmaceutical industry's demands represented a "trade-off" for the UK. "It was a concern on the Swiss side and a concern on our side," Bryant told POLITICO at an event celebrating the deal. "But I'm very glad that we managed to come to an agreement on that."
The Commitments Under the Deal
Under the terms of the upgraded trade agreement, both sides will lock in the current level of intellectual property protection, including the Supplementary Protection Certificate (search) (SPC) and Regulatory Data Protection (RDP). While SPCs extend patent protection for pharma companies beyond the standard 20-year term to compensate for time lost during the medicines approval process, RDP stops generic competitors from using pharma companies' clinical trial data to gain regulatory approval for cheaper copies.
The UK has committed to maintain its existing 10-year RDP period and five years of protection for SPCs. Together, these protections give pharmaceutical companies time to recoup the cost of developing new medicines before cheaper alternatives can enter the market.
Industry Welcomes Stability
The pharmaceutical industry welcomed the commitments, viewing them as making Britain a more predictable place to invest in research, manufacturing, and clinical trials.
"The UK and Swiss governments have made explicit their commitment to maintain a strong and proportionate IP regime, which is one of the long-standing foundations of life science innovation in both countries," said Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (search) (ABPI). "This message of stability helpfully underpins our efforts to drive more investment in both countries."
Shaun Grady, AstraZeneca UK chair, added: "It is particularly important that both countries have recognised the importance of upholding vital IP standards to enable reinvestment in new research for the next wave of medical breakthroughs."
Campaigners Warn of NHS Cost Impact
Health campaigners argue the government is signing away the levers it has to curb the power of the pharmaceutical industry, potentially increasing costs for the NHS.
"The status quo is already deeply damaging for the NHS," said Diarmaid McDonald, executive director at Just Treatment. "We are entrenching a system which is failing patients right now, and we're entrenching a power dynamic that weighs far too heavily in the interests of the industry."
McDonald further warned: "If a future government wants to do something about the unsustainable business model of the pharmaceutical industry, it will not be able to do that because they've signed away the power to do that within this trade agreement."
In a statement, the UK Government said the deal "maintains the existing balance between supporting pharmaceutical innovation and the NHS's access to lower-cost generic medicines." However, McDonald characterized the broader pattern of trade policy as assuming "every pharma lobby demand is good for the economy regardless of the effect on patients."
Broader Context
The deal follows a controversial pharma agreement Britain signed with the Trump administration, which promised to increase NHS spending on new medicines in exchange for tariff-free access to the American pharmaceutical market for at least three years. That deal is currently facing a legal challenge after ministers were accused of breaching parliamentary protocol to rewrite NHS drug pricing rules.
Asked about concerns within the Department of Health and Social Care regarding the Swiss deal, Bryant acknowledged internal tensions: "There's always a bit of a negotiation between different departments and sometimes different departments are a bit more anxious than others about different elements. So sometimes you spend more time negotiating with your own government than you do with the people on the other side of the table."